143 related articles for article (PubMed ID: 35580403)
1. Neuronal intermediate filament paraneoplastic autoimmunity complicating avelumab therapy of Merkel cell carcinoma.
Dinoto A; McKeon A; Vattemi G; Carta S; Ferrari S; Mariotto S
J Neuroimmunol; 2022 Jul; 368():577882. PubMed ID: 35580403
[TBL] [Abstract][Full Text] [Related]
2. Neuronal intermediate filament IgGs in CSF: Autoimmune Axonopathy Biomarkers.
McKeon A; Shelly S; Zivelonghi C; Basal E; Dubey D; Flanagan E; Madhavan AA; Mariotto S; Toledano M; Tracy JA; Zekeridou A; Pittock SJ
Ann Clin Transl Neurol; 2021 Feb; 8(2):425-439. PubMed ID: 33369283
[TBL] [Abstract][Full Text] [Related]
3. Paraneoplastic neuronal intermediate filament autoimmunity.
Basal E; Zalewski N; Kryzer TJ; Hinson SR; Guo Y; Dubey D; Benarroch EE; Lucchinetti CF; Pittock SJ; Lennon VA; McKeon A
Neurology; 2018 Oct; 91(18):e1677-e1689. PubMed ID: 30282771
[TBL] [Abstract][Full Text] [Related]
4. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
Kaufman HL; Russell J; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Linette GP; Milella M; Brownell I; Lewis KD; Lorch JH; Chin K; Mahnke L; von Heydebreck A; Cuillerot JM; Nghiem P
Lancet Oncol; 2016 Oct; 17(10):1374-1385. PubMed ID: 27592805
[TBL] [Abstract][Full Text] [Related]
5. Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial.
Lambert J; Marrel A; D'Angelo SP; Burgess MA; Chmielowski B; Fazio N; Gambichler T; Grob JJ; Lebbé C; Robert C; Russell J; Güzel G; Bharmal M
Patient; 2020 Aug; 13(4):457-467. PubMed ID: 32472503
[TBL] [Abstract][Full Text] [Related]
6. Avelumab for the treatment of metastatic Merkel cell carcinoma.
Cordes LM; Gulley JL
Drugs Today (Barc); 2017 Jul; 53(7):377-383. PubMed ID: 28837181
[TBL] [Abstract][Full Text] [Related]
7. Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East.
Ascierto PA; Orlova K; Grignani G; Dudzisz-Śledź M; Fenig E; Chiarion Sileni V; Fazio N; Samimi M; Mortier L; Gebhardt C; Kramkimel N; Steven N; Bechter O; Arance A; Benincasa E; Kostkova L; Costa N; Lorigan P
Int J Cancer; 2021 Dec; 149(11):1926-1934. PubMed ID: 34310716
[TBL] [Abstract][Full Text] [Related]
8. Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel.
Cowey CL; Liu FX; Kim R; Boyd M; Fulcher N; Krulewicz S; Kasturi V; Bhanegaonkar A
Future Oncol; 2021 Jun; 17(18):2339-2350. PubMed ID: 33709776
[TBL] [Abstract][Full Text] [Related]
9. Avelumab: A Review in Metastatic Merkel Cell Carcinoma.
Shirley M
Target Oncol; 2018 Jun; 13(3):409-416. PubMed ID: 29799096
[TBL] [Abstract][Full Text] [Related]
10. Hyperprogression of Merkel cell carcinoma after avelumab treatment.
Pirker R; Fink A; Stella A; Stifter L; Posch C
J Eur Acad Dermatol Venereol; 2023 May; 37(5):e675-e677. PubMed ID: 36662601
[No Abstract] [Full Text] [Related]
11. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.
D'Angelo SP; Russell J; Lebbé C; Chmielowski B; Gambichler T; Grob JJ; Kiecker F; Rabinowits G; Terheyden P; Zwiener I; Bajars M; Hennessy M; Kaufman HL
JAMA Oncol; 2018 Sep; 4(9):e180077. PubMed ID: 29566106
[TBL] [Abstract][Full Text] [Related]
12. Avelumab: a new standard for treating metastatic Merkel cell carcinoma.
Baker M; Cordes L; Brownell I
Expert Rev Anticancer Ther; 2018 Apr; 18(4):319-326. PubMed ID: 29482384
[TBL] [Abstract][Full Text] [Related]
13. Avelumab Immunotherapy: Management of Adverse Events Associated With New Treatment for Merkel Cell Carcinoma.
Ugolini H; Bryan J; Hennessy M; Kaufman HL; D'Angelo S
Clin J Oncol Nurs; 2019 Feb; 23(1):E1-E9. PubMed ID: 30682006
[TBL] [Abstract][Full Text] [Related]
14. A Case Report of Leptomeningeal Carcinomatosis Secondary to Recurrent Merkel Cell Carcinoma after Avelumab.
Mendoza P; Chuang KL
Perm J; 2021 May; 25():. PubMed ID: 33970097
[TBL] [Abstract][Full Text] [Related]
15. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Georges S; Shah P; Ellers-Lenz B; Bajars M; Güzel G; Nghiem PT
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414862
[TBL] [Abstract][Full Text] [Related]
16. Case of fulminant type 1 diabetes induced by the anti-programmed death-ligand 1 antibody, avelumab.
Shibayama Y; Kameda H; Ota S; Tsuchida K; Cho KY; Nakamura A; Miyoshi H; Atsumi T
J Diabetes Investig; 2019 Sep; 10(5):1385-1387. PubMed ID: 30738003
[TBL] [Abstract][Full Text] [Related]
17. Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab.
Grisic AM; Xiong W; Tanneau L; Jönsson S; Friberg LE; Karlsson MO; Dai H; Zheng J; Girard P; Khandelwal A
Clin Cancer Res; 2022 Apr; 28(7):1363-1371. PubMed ID: 34921021
[TBL] [Abstract][Full Text] [Related]
18. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up.
D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Xiong H; Guezel G; Nghiem PT
ESMO Open; 2021 Dec; 6(6):100290. PubMed ID: 34715570
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma.
Hu P; Dai HI; Bourdage J; Zhou D; Trang K; Kowalski K; Bello C; Hibma J; Khandelwal A; Cowan K; Dong J; Venkatakrishnan K; Gao W
Clin Transl Sci; 2024 Mar; 17(3):e13730. PubMed ID: 38411318
[TBL] [Abstract][Full Text] [Related]
20. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.
Kaufman HL; Russell JS; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Milella M; Brownell I; Lewis KD; Lorch JH; von Heydebreck A; Hennessy M; Nghiem P
J Immunother Cancer; 2018 Jan; 6(1):7. PubMed ID: 29347993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]